Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TR), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TR for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Viking Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

CONFERENCE CALL SCHEDULED FOR 4:30 P.M. ET TODAY -- PHASE 3 VANQUISH 1 & 2 TRIALS FOR SUBCUTANEOUS VK2735 IN OBESITY FULLY ENROLLED AND ADVANCING -- -- ORAL PHASE 3 VK2735 TRIAL INITIATION EXPECTED 4Q26 -- -- VK2735 MAINTENANCE DOSING DATA EXPECTED 3Q26 -- -- PHASE 1 STUDY OF AMYLIN AGONIST VK3019 UNDERWAY -- -- STRONG QUARTER-END CASH POSITION OF $502 MILLION -- SAN DIEGO, JULY 29, 2026 /PRNEWSWIRE/ -- VIKING THERAPEUTICS, INC. (VIKING) (NASDAQ: VKTX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF NOVEL THERAPIES FOR METABOLIC AND ENDOCRINE DISORDERS, TODAY ANNOUNCED ITS FINANCIAL RESULTS FOR THE SECOND QUARTER AND SIX MONTHS ENDED JUNE 30, 2026, AND PROVIDED AN UPDATE ON ITS CLINICAL PIPELINE AND OTHER CORPORATE DEVELOPMENTS.

VIKING THERAPEUTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

EXPERIENCED EXECUTIVE BRINGS OVER TWO DECADES OF LEADERSHIP ACROSS HEALTHCARE, DIGITAL HEALTH AND COMMERCIALIZATION SAN DIEGO,, JULY 23, 2026 /PRNEWSWIRE/ -- VIKING THERAPEUTICS, INC. (VIKING) (NASDAQ: VKTX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF NOVEL THERAPIES FOR METABOLIC AND ENDOCRINE DISORDERS,TODAY ANNOUNCED THE APPOINTMENT OF DOROTHY GEMMELL TO ITS BOARD OF DIRECTORS, EFFECTIVE IMMEDIATELY. MS. GEMMELL IS A HIGHLY EXPERIENCED EXECUTIVE AND BOARD ADVISOR WITH OVER 25 YEARS OF LEADERSHIP EXPERIENCE ACROSS HEALTHCARE, DIGITAL HEALTH, AND COMMERCIALIZATION.

VIKING THERAPEUTICS APPOINTS DOROTHY GEMMELL TO BOARD OF DIRECTORS

CONFERENCE CALL SCHEDULED FORWEDNESDAY, JULY 29, AT 4:30 P.M. EASTERN TIME SAN DIEGO, JULY 22, 2026 /PRNEWSWIRE/ -- VIKING THERAPEUTICS, INC. ("VIKING") (NASDAQ: VKTX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF NOVEL THERAPIES FOR METABOLIC AND ENDOCRINE DISORDERS, TODAY ANNOUNCED THAT THE COMPANY WILL RELEASE FINANCIAL RESULTS FOR THE SECOND QUARTER OF 2026 AFTER THE MARKET CLOSE ONWEDNESDAY, JULY 29, 2026.

VIKING THERAPEUTICS TO REPORT FINANCIAL RESULTS FOR SECOND QUARTER 2026 ON JULY 29, 2026

NEW YORK, JULY 21, 2026 /PRNEWSWIRE/ -- KUEHN LAW, PLLC, A SHAREHOLDER LITIGATION LAW FIRM, IS INVESTIGATING WHETHER CERTAIN OFFICERS AND DIRECTORS OF VIKING THERAPEUTICS, INC. (NASDAQ: VKTX) BREACHED THEIR FIDUCIARY DUTIES TO SHAREHOLDERS. THE INVESTIGATION CONCERNS POTENTIAL SELF-DEALING.

KUEHN LAW ENCOURAGES INVESTORS OF VIKING THERAPEUTICS, INC. TO CONTACT LAW FIRM

NEW YORK, JULY 16, 2026 (GLOBE NEWSWIRE) -- KUEHN LAW, PLLC, A SHAREHOLDER LITIGATION LAW FIRM, IS INVESTIGATING WHETHER CERTAIN OFFICERS AND DIRECTORS OF VIKING THERAPEUTICS, INC. (NASDAQ: VKTX) BREACHED THEIR FIDUCIARY DUTIES TO SHAREHOLDERS. THE INVESTIGATION CONCERNS POTENTIAL SELF-DEALING. SHAREHOLDERS MAY BE ENTITLED TO DAMAGES AND CORPORATE GOVERNANCE REFORMS.

SINGLE ASCENDING DOSE STUDY EVALUATING SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF VK3019 POTENTIAL TO FURTHER EXPAND VIKING'STREATMENT OPTIONS FOR WEIGHT LOSS SAN DIEGO, JUNE 24, 2026 /PRNEWSWIRE/ -- VIKING THERAPEUTICS, INC. ("VIKING") (NASDAQ: VKTX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF NOVEL THERAPIES FOR METABOLIC AND ENDOCRINE DISORDERS, ANNOUNCED TODAY THE INITIATION OF A PHASE 1 SINGLE ASCENDING DOSE (SAD) CLINICAL TRIAL OF VK3019, AN INVESTIGATIONAL DUAL AMYLIN AND CALCITONIN RECEPTOR AGONIST (DACRA). VK3019 IS BEING DEVELOPED AS A POTENTIAL TREATMENT OPTION FOR WEIGHT LOSS.

VIKING THERAPEUTICS ANNOUNCES INITIATION OF PHASE 1 STUDY TO EVALUATE NOVEL AMYLIN RECEPTOR AGONIST VK3019 IN HEALTHY ADULTS

EXPERIENCED BIOTECH LEADER WITH MORE THAN TWO DECADES OF EXPERIENCE ADVANCING THERAPIES FROM DISCOVERY THROUGH REGULATORY APPROVAL SAN DIEGO, JUNE 11, 2026 /PRNEWSWIRE/ --VIKING THERAPEUTICS, INC. (VIKING) (NASDAQ: VKTX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF NOVEL THERAPIES FOR METABOLIC AND ENDOCRINE DISORDERS, TODAY ANNOUNCED THE APPOINTMENT OF HUBERT C. CHEN, M.D.

VIKING THERAPEUTICS ANNOUNCES APPOINTMENT OF HUBERT C. CHEN, M.D.

SAN DIEGO, MAY 21, 2026 /PRNEWSWIRE/ -- VIKING THERAPEUTICS, INC. ("VIKING") (NASDAQ: VKTX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF NOVEL THERAPIES FOR METABOLIC AND ENDOCRINE DISORDERS, TODAY ANNOUNCED THAT IT WILL PARTICIPATE AT THE WILLIAM BLAIR46THANNUAL GROWTH STOCK CONFERENCE AND THE JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN JUNE. DETAILS OF THE COMPANY'S PARTICIPATION ARE AS FOLLOWS: WILLIAM BLAIR46THANNUAL GROWTH STOCK CONFERENCE DETAILS: VIKING MANAGEMENT WILL DELIVER A CORPORATE PRESENTATION, FOLLOWED BY A BREAKOUT SESSION, AND PARTICIPATE IN INVESTOR MEETINGS.CONFERENCE DATES: JUNE 2-4, 2026PRESENTATION DATE/TIME: TUESDAY, JUNE 2ND AT 2:00 PM  2:30 PM CTBREAKOUT SESSION: TUESDAY, JUNE 2ND AT 2:40 PM  3:10 PM CTLOCATION: CHICAGO, IL JEFFERIES GLOBAL HEALTHCARE CONFERENCE DETAILS: VIKING MANAGEMENT WILL PARTICIPATE IN A FIRESIDE CHAT AND INVESTOR MEETINGS.

VIKING THERAPEUTICS TO PARTICIPATE AT UPCOMING INVESTOR CONFERENCES

ORAL VK2735 DEMONSTRATED EARLY, PROGRESSIVE WEIGHT LOSS FROM WEEK 1 THROUGH WEEK 13 WITHOUT A PLATEAU DOSE-DEPENDENT WEIGHT LOSS OBSERVED ACROSS ALL VK2735 COHORTS, WITH THE HIGHEST DOSE ACHIEVING A MEAN REDUCTION OF UP TO 12.2% (26.6 LBS) FROM BASELINE AT WEEK 13 BASELINE CHARACTERISTICS IN THE ONGOING PHASE 3 VANQUISH-1 STUDY OF VK2735 IN ADULTS WITH OBESITY WERE ALSO PRESENTED IN A SECOND POSTER AT THE CONFERENCE SAN DIEGO, MAY 12, 2026 /PRNEWSWIRE/ -- VIKING THERAPEUTICS, INC. ("VIKING") (NASDAQ: VKTX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF NOVEL THERAPIES FOR METABOLIC AND ENDOCRINE DISORDERS, TODAY PRESENTED ADDITIONAL DATA FROM ITS PHASE 2 VENTURE-ORAL DOSING TRIAL EVALUATING THE ORAL TABLET FORMULATION OF VK2735 AT THE EUROPEAN CONGRESS ON OBESITY (ECO) IN ISTANBUL, TRKIYE. VK2735 IS A DUAL AGONIST OF THE GLUCAGON-LIKE PEPTIDE 1 (GLP-1) AND GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE (GIP) RECEPTORS, IN DEVELOPMENT WITH SUBCUTANEOUS AND ORAL FORMULATIONS FOR THE POTENTIAL TREATMENT OF VARIOUS METABOLIC DISORDERS.

VIKING THERAPEUTICS PRESENTS DATA FROM ITS 13-WEEK PHASE 2 VENTURE-ORAL DOSING TRIAL OF VK2735 AT EUROPEAN CONGRESS ON OBESITY (ECO) 2026

POSTER PRESENTATIONS HIGHLIGHT DATA FROM 13-WEEK PHASE 2 VENTURE-ORAL TRIAL OF VK2735 AND PARTICIPANT CHARACTERISTICS FROM PHASE 3 VANQUISH-1 TRIAL OF SUBCUTANEOUS VK2735 SAN DIEGO, MAY 5, 2026 /PRNEWSWIRE/ --VIKING THERAPEUTICS, INC. ("VIKING") (NASDAQ: VKTX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF NOVEL THERAPIES FOR METABOLIC AND ENDOCRINE DISORDERS, ANNOUNCED TODAY THAT IT WILL PRESENT TWO POSTERS ON ITS VK2735 PROGRAM AT THE 33RD EUROPEAN CONGRESS ON OBESITY (ECO) TAKING PLACE IN ISTANBUL, TRKIYE ON MAY 12-15, 2026. VK2735 IS A DUAL AGONIST OF THE GLUCAGON-LIKE PEPTIDE 1 (GLP-1) AND GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE (GIP) RECEPTORS THAT VIKING IS DEVELOPING IN SUBCUTANEOUS AND ORAL FORMULATIONS FOR THE POTENTIAL TREATMENT OF VARIOUS METABOLIC DISORDERS, INCLUDING OBESITY.

Viking Therapeutics, Inc.

VKTX

Price

Financial Reports

No items found.

Press Releases

Viking Therapeutics, Inc.

VKTX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

VKTX